I agree that this site is using cookies. You can find further informations
here
.
X
Login
Merkliste (
0
)
Home
About us
Home About us
Our history
Profile
Press & public relations
Friends
The library in figures
Exhibitions
Projects
Training, internships, careers
Films
Services & Information
Home Services & Information
Lending and interlibrary loans
Returns and renewals
Training and library tours
My Account
Library cards
New to the library?
Download Information
Opening hours
Learning spaces
PC, WLAN, copy, scan and print
Catalogs and collections
Home Catalogs and Collections
Rare books and manuscripts
Digital collections
Subject Areas
Our sites
Home Our sites
Central Library
Law Library (Juridicum)
BB Business and Economics (BB11)
BB Physics and Electrical Engineering
TB Engineering and Social Sciences
TB Economics and Nautical Sciences
TB Music
TB Art & Design
TB Bremerhaven
Contact the library
Home Contact the library
Staff Directory
Open access & publishing
Home Open access & publishing
Reference management: Citavi & RefWorks
Publishing documents
Open Access in Bremen
zur Desktop-Version
Toggle navigation
Merkliste
1 Ergebnisse
1
Efficacy and safety of canakinumab as a second line biologi..:
Ekaterina Alexeeva
;
Elizaveta Krekhova
;
Tatyana Dvoryakovskaya
...
https://www.frontiersin.org/articles/10.3389/fped.2023.1114207/full. , 2023
Link:
https://doi.org/10.3389/fped.2023.1114207
RT Journal T1
Efficacy and safety of canakinumab as a second line biologic after tocilizumab treatment failure in children with systemic juvenile idiopathic arthritis: A single-centre cohort study using routinely collected health data
UL https://suche.suub.uni-bremen.de/peid=base-ftdoajarticles:oai:doaj.org_article:c815f5c7534443638840395b3337e769&Exemplar=1&LAN=DE A1 Ekaterina Alexeeva A1 Elizaveta Krekhova A1 Tatyana Dvoryakovskaya A1 Ksenia Isaeva A1 Aleksandra Chomakhidze A1 Evgeniya Chistyakova A1 Olga Lomakina A1 Rina Denisova A1 Anna Mamutova A1 Anna Fetisova A1 Marina Gautier A1 Dariya Vankova A1 Ivan Kriulin A1 Ruslan Saygitov PB Frontiers Media S.A. YR 2023 K1 systemic juvenile idiopathic arthritis K1 tocilizumab K1 canakinumab K1 second-line biologic K1 switching K1 Pediatrics K1 RJ1-570 JF https://www.frontiersin.org/articles/10.3389/fped.2023.1114207/full LK http://dx.doi.org/https://doi.org/10.3389/fped.2023.1114207 DO https://doi.org/10.3389/fped.2023.1114207 SF ELIB - SuUB Bremen
Export
RefWorks (nur Desktop-Version!)
Flow
(Zuerst in
Flow
einloggen, dann importieren)